| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eb81bf5f72f9efb30a9d6ea95dd7300a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_03c4720e107878f494e6eb5a8e8500ea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37b36726b8c2d3a2fe627ab8caf1e052
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37f4922dfb7777b019e504b885211b8e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-31 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-117
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0693 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-117 |
| filingDate |
2017-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_65dd2882340a83c77ed0833ee2639442
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d01003d77f36581944ec746be6096d12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6c17613744fb4722a492aad28112bd1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8a10d3d8077f10ca03c2eb27c6d824e0 |
| publicationDate |
2019-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3538658-A1 |
| titleOfInvention |
Tlr3 agonist for use for inducing apoptosis in senescent cancer cells |
| abstract |
The present invention relates to a TLR3 agonist for use for inducing apoptosis in senescent cancer cells, in particular to a TLR3 agonist for use as a medicament for inducing apoptosis in senescent cancer cells. In particular, it relates to a TLR3 agonist for use for the treatment of cancer, optionally in combination with a chemotherapeutic agent or with radiotherapy. It further relates to a pharmaceutical composition comprising a TLR3 agonist and a chemotherapeutic agent. |
| priorityDate |
2016-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |